Off-Label Benralizumab in Severe Non-Necrotizing Eosinophilic Vasculitis following Critical COVID-19 Disease and in DRESS

Benralizumab is a humanized recombinant mAb that binds to the interleukin 5 receptor (IL-5R) expressed on eosinophils and is approved for the treatment of severe eosinophilic asthma. There are a series of severe eosinophilic disorders that may benefit from this treatment, and it could be a life-savi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pintea, Irena, Muntean, Ioana Adriana, Dobrican, Carmen Teodora, Miron, Nicolae, Deleanu, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693026/
https://www.ncbi.nlm.nih.gov/pubmed/36431118
http://dx.doi.org/10.3390/jcm11226642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693026/
https://www.ncbi.nlm.nih.gov/pubmed/36431118
http://dx.doi.org/10.3390/jcm11226642

Ejemplares similares